...Histologically or cytologically confirmed, locally advanced or metastatic EGFR wild-type, ALK wild-type, and other driver negative (AGA negative, including MET 14 exon jump mutation, ROS1 rearrangement, BRAF V600 mutation, NTRK fusion, RET rearrangement, HER2 mutation, Patients with HER2 amplification (> 3.2 copies), KRAS G12 mutation (e.g., G12C, G12D, G12V, etc.) negative), non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma), who only received anti-PD-1 /PD-L1 monoclonal antibody + platino-containing dimorphization and disease progression or intolerance at the first line;...

...Patients with locally advanced or metastatic EGFR wild-type ALK wild-type lung cancer, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody and platinum-based chemotherapy, or progression or intolerance after first-line treatment with anti-PD-1/PD-L1 monoclonal antibody; 6....

This phase II study enrolled patients with locally advanced or metastatic EGFR/ALK wild-type NSCLC who had failed first-line anti-PD-1/L1 therapy, with or without platinum-based chemotherapy...Among 22 evaluable pts in schedule 1 the ORR was 45.5% (10/22, [24.5, 67.8]) and the DCR was 68.2% (15/22, [45.1, 86.1])....SI-B001 plus docetaxel demonstrated antitumor activity in locally advanced or metastatic NSCLC EGFR/ALK wild-type pts who failed on prior first-line anti-PD-1/L1 antibody plus PBC, especially without AGA.